Treatment of ankylosing spondylitis and other spondyloarthritides

Current Opinion in Rheumatology

Volumn 21, Issue 4, 2009, Pages 324-334

  Braun, Juergen ^a   Baraliakos, Xenofon ^a  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

Author keywords

Ankylosing spondylitis; Disease modifying antirheumatic drugs; Physiotherapy; Psoriatic arthritis; Spondylarthritis; Surgery; Therapy; Tumour necrosis factor blockers

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CELECOXIB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DOUBLE STRANDED DNA ANTIBODY; EFALIZUMAB; ETANERCEPT; ETORICOXIB; GLUCOCORTICOID; GOLIMUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RADIUM 224; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; ALOPECIA AREATA; AMYOTROPHIC LATERAL SCLEROSIS; ANKYLOSING SPONDYLITIS; ANKYLOSIS; ANTIBODY PRODUCING CELL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ASPERGILLOSIS; BIOLOGICAL THERAPY; CARDIOVASCULAR RISK; CAUDA EQUINA SYNDROME; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL; COLD INJURY; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DERMATITIS HERPETIFORMIS; DIABETES MELLITUS; DIET THERAPY; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; ENTHESITIS; ERYTHEMA NODOSUM; FUNCTIONAL ASSESSMENT; GROUP THERAPY; HISTOPATHOLOGY; HOME CARE; HUMAN; HYPERTENSION; IMMUNOTHERAPY; IRIDOCYCLITIS; KERATODERMA BLENNORRHAGICA; KINESIOTHERAPY; LICHEN PLANUPILARIS; LUPUS VULGARIS; MEDLINE; MONARTHRITIS; MULTIPLE SCLEROSIS; MYELITIS; MYELOID LEUKEMIA; NEVUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; OSTEOTOMY; PATIENT EDUCATION; PERIPHERAL NEUROPATHY; PHYSICAL CAPACITY; PHYSIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULOSIS; PUSTULOSIS PALMOPLANTARIS; QUALITY OF LIFE; RELIGION; REMISSION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SACROILIITIS; SARCOIDOSIS; SKIN TOXICITY; SPINE SURGERY; SPONDYLOARTHROPATHY; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TAI CHI; TEMPOROMANDIBULAR JOINT DISORDER; TOTAL HIP PROSTHESIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; DISEASE PROGRESSION; HUMANS; IMMUNOLOGIC FACTORS; METHOTREXATE; OSTEOGENESIS; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67149106015     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32832c6674     Document Type: Review

References (109)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369:1379-1390. (Pubitemid 46590387)
2. Mengshoel AM. Living with a fluctuating illness of ankylosing spondylitis: a qualitative study. Arthritis Rheum 2008; 59:1439-1444.
3. Landewé R, Dougados M, Mielants H, et al. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 2008. [Epub ahead of print] An important clarification implying that function in ankylosing spondylitis is independently determined by inflammation and new bone formation.
4. Stone MA, Pomeroy E, Keat A, et al. Assessment of the impact of flares in ankylosing spondylitis disease activity using the Flare Illustration. Rheumatology (Oxford) 2008; 47:1213-1218. (Pubitemid 352038229)
5. Pradeep DJ, Keat A, Gaffney K. Predicting outcome in ankylosing spondylitis. Rheumatology (Oxford) 2008; 47:942-945. (Pubitemid 351865912)
6. Kiltz U, van der Heijde D, Mielants H, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis: the patient version. Ann Rheum Dis 2008. [Epub ahead of print] Important step towards cooperation with patients in the dissemination, the evaluation and the development of recommendations is shown in this article.
7. Gossec L, Dougados M, Phillips C, et al., ASAS (Assessment in AS international working group). Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists. Ann Rheum Dis 2008; 67:782-788.
8. Sidiropoulos PI, Hatemi G, Song IH, et al. Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology (Oxford) 2008; 47:355-361. (Pubitemid 351267206)
9. Dougados M, Luo MP, Maksymowych WP, et al., ATLAS STUDY GROUP. Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial. Arthritis Rheum 2008; 59:553-560. The above article showed that the concept of the 'PASS' may become another clinically relevant measure to assess the burden of disease in rheumatic diseases.
10. Berthelot JM, Tortellier L, Lavy-Bregeon D, et al. High intraindividual week-to-week variability in BASDAI and BASFI values: are several evaluations needed before starting or stopping TNFalpha antagonist therapy for spondyloarthropathies? Joint Bone Spine 2008; 75:167-171.
11. Braun J, Davis J, Dougados M, et al., ASAS Working Group. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65:316-320.
12. Song IH, Rudwaleit M, Listing J, Sieper J. Comparison of the BASDAI and the modified BASDAI (mini-BASDAI) in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Ann Rheum Dis 2008. [Epub ahead of print]
13. Lukas C, Landewé R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2008. [Epub ahead of print]
14. van der Heijde D, Lie E, Kvien TK, et al. The ASDAS is a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2008. [Epub ahead of print] The above article showed that this new tool to assess disease activity in ankylosing spondylitis would primarily serve for clinical trials, for example, to calculate patient numbers.
15. Zochling J, Sieper J, van der Heijde D, Braun J. Assessment in Ankylosing Spondylitis International Working Group. Collaborators: Weber U, Rudwaleit M, Leirisalo-Repo M, Collantes-Estévez E, van der Horst-Bruinsma I, Géher P, Kvien T, deVlam K, I Ostergaard M, Maksymowych W. Development of a core set of domains for data collection in cohorts of patients with ankylosing spondylitis receiving antitumor necrosis factor-alpha therapy. J Rheumatol 2008; 35:1079-1082.
16. Song IH, Poddubnyy DA, Rudwaleit M, Sieper J. Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum 2008; 58:929-938. A good review on the role of NSAIDs in ankylosing spondylitis. (Pubitemid 351563993)
17. Jarrett SJ, Sivera F, Cawkwell LS, et al. Clinical and MRI findings in ankylosing spondylitis patients eligible for anti-TNF therapy: response to short-term etoricoxib therapy. Ann Rheum Dis 2008. [Epub ahead of print]
18. Sieper J, Klopsch T, Richter M, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis 2008; 67:323-329. (Pubitemid 351281265)
19. Poddubnyy DA, Song IH, Sieper J. The safety of celecoxib in ankylosing spondylitis treatment. Expert Opin Drug Saf 2008; 7:401-409.
20. Maksymowych WP. Do bisphosphonates and statins have a role in spondyloarthritis management? Curr Rheumatol Rep 2008; 10:364-370.
21. Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of antitumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008; 59:234-240. An interesting comparison of the efficacy of TNF blockers in different rheumatic diseases is shown suggesting that these agents work better in SpAs than in RA. (Pubitemid 351272960)
22. Inman RD, Davis JC Jr, Heijde DV, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58:3402-3412. An RCT showing that a new anti-TNF agent, golimumab, which only needs to be administered once a month, works well in ankylosing spondylitis.
23. Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008; 58:1981-1991. An important study showing the good efficacy of adalimumab in early axial SpA patients (who do not fulfil the New York criteria). (Pubitemid 351988090)
24. Breban M, Ravaud P, Claudepierre P, et al., French Ankylosing Spondylitis Infliximab Network. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008; 58:88-97. An important study showing that continuous therapy with TNF blockers is better than on-demand strategies in ankylosing spondylitis, whereas the addition of MTX to infliximab shows no clear benefit for patients with predominant spinal pain.
25. Li EK, Griffith JF, Lee VW, et al. Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology (Oxford) 2008; 47:1358-1363.
26. Haibel H, Song IH, Rudwaleit M, et al. Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice. Clin Exp Rheumatol 2008; 26:247-252. (Pubitemid 351659131)
27. Griffoul I, Giraudeau B, Mulleman D, et al. Infliximab for treating axial spondylarthropathy in everyday practice. Joint Bone Spine 2008. [Epub ahead of print]
28. Gérard S, Le Goff B, Maugars Y, Berthelot JM. Six-month response to anti-TNF drugs in axial spondylarthropathy according to the fulfillment or not of New-York criteria for ankylosing spondylitis or French recommendations for anti-TNF use: a 'real life' retrospective study on 175 patients. Joint Bone Spine 2008; 75:680-687.
29. Levälampi T, Korpela M, Vuolteenaho K, Moilanen E. Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment. Scand J Rheumatol 2008; 37:6-12.
30. Coates LC, Cawkwell LS, Ng NW, et al. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology (Oxford) 2008; 47:897-900. (Pubitemid 351796381)
31. Coates LC, Cawkwell LS, Ng NW, et al. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Ann Rheum Dis 2008; 67:717-719. (Pubitemid 351571940)
32. Pradeep DJ, Keat AC, Gaffney K, et al. Switching anti-TNF therapy in ankylosing spondylitis. Rheumatology (Oxford) 2008; 47:1726-1727.
33. Xu Z, Seitz K, Fasanmade A, et al. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 2008; 48:681-695. (Pubitemid 351713154)
34. Braun J, Baraliakos X, Listing J, et al. Persistent clinical efficacy and safety of antitumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008; 67:340-345. (Pubitemid 351281268)
35. Davis JC Jr, van der Heijde DM, Braun J, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008; 67:346-352. (Pubitemid 351281269)
36. Braun J, Deodhar A, Dijkmans B, et al., Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 2008; 59:1270-1278.
37. van der Heijde D, Schiff MH, Sieper J, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2008. [Epub ahead of print]
38. Revicki DA, Luo MP, Wordsworth P, et al. ATLAS Study Group. Collaborators: Birbara C, Borofsky M, Bratt J, Braun J, Breban M, Cantini F, Collantes E, Cush JJ, Dijkmans BA, DiVittorio G, Dougados M, Flynn J, Halter D, Jackson C, Keroack B, Kivitz A, Kremer J, Lautzenheiser R, Le Loët X, Matsumoto AK, Mease PJ, Mörck B, Moreland L, Morgan J, Mulero J, Olivieri I, Palmer W, Reveille JD, Ruderman E, Rupp P, Salvarani C, Sayers M, Schiff MH, Scott D, Sieper J, Sturrock RD, Torre J, van der Heijde D, Veys E, Westhovens R, Willis L, Wordsworth BP, Zeidler H. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the Adalimumab Trial Evaluating Long-Term Safety and Efficacy for Ankylosing Spondylitis (ATLAS). Rheumatol 2008; 35:1346-1353.
39. Boonen A, Patel V, Traina S, et al. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept. J Rheumatol 2008; 35:662-667.
40. Kobelt G, Sobocki P, Mulero J, et al. The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain: comparison of clinical trial and clinical practice data. Scand J Rheumatol 2008; 37:62-71.
41. Wailoo A, Bansback N, Chilcott J. Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance. Rheumatology (Oxford) 2008; 47:119-120. (Pubitemid 351168216)
42. Troppmann L, Karsh J, Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada. The percentage of patients with seronegative spondyloarthritis requiring magnetic resonance imaging to meet the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada guidelines for access to antitumor necrosis factor treatment. J Rheumatol 2008; 35:658-661.
43. van der Heijde D, Pangan AL, Schiff MH, et al., ATLAS Study Group. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis 2008; 67:1218-1221. An interesting subanalysis with a small number of patients who benefit from adalimumab therapy despite advanced spinal ankylosis.
44. Cheung PP, Tymms KE, Wilson BJ, et al. Infliximab in severe active ankylosing spondylitis with spinal ankylosis. Intern Med J 2008; 38:396-401. (Pubitemid 351871972)
45. Rudwaleit M, Rødevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2008. [Epub ahead of print]
46. Wendling D, Augé B, Streit G, et al. Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis. Joint Bone Spine 2008; 75:510-511.
47. Rodríguez-Escalera C, Fernández-Nebro A. The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B. Rheumatology (Oxford) 2008; 47:1732-1733.
48. Baeten D, Kruithof E, Breban M, Tak PP. Spondylarthritis in the absence of B lymphocytes. Arthritis Rheum 2008; 58:730-733.
49. Polzer K, Baeten D, Soleiman A, et al. Tumour necrosis factor blockade increases lymphangiogenesis in murine and human arthritic joints. Ann Rheum Dis 2008; 67:1610-1616.
50. Vandooren B, Cantaert T, ter Borg M, et al. Tumor necrosis factor alpha drives cadherin 11 expression in rheumatoid inflammation. Arthritis Rheum 2008; 58:3051-3062.
51. Lories RJ, Derese I, Luvten FP, de Vlam K. Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment. Clin Exp Rheumatol 2008; 26:96-102.
52. van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008; 58:1324-1331. (Pubitemid 351705922)
53. van der Heijde D, Landewé R, Baraliakos X, et al., Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008; 58:3063-3070. One of the important articles showing no benefit from anti-TNF therapy on radiographic scores of patients with ankylosing spondylitis using the mSASSS.
54. Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum 2008; 58:649-656. A good review on the relative importance of inflammation and new bone formation in ankylosing spondylitis.
55. Appel H, Rudwaleit M, Sieper J. Relevance of osteoproliferation as an outcome parameter in ankylosing spondylitis. Nat Clin Pract Rheumatol 2008; 4:578-579.
56. Baraliakos X, Listing J, Rudwaleit M, et al. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 2008; 10:R104. An interesting study providing evidence for a link and a dissociation of spinal inflammation and new bone formation in ankylosing spondylitis.
57. Braun J, Sieper J. What is the most important outcome parameter in ankylosing spondylitis? Rheumatology (Oxford) 2008; 47:1738-1740. An important discussion on the relative importance of patient reported outcomes vs. disease modification in ankylosing spondylitis.
58. Zhu TY, Tarn LS, Lee VW, et al. Costs and quality of life of patients with ankylosing spondylitis in Hong Kong. Rheumatology (Oxford) 2008; 47:1422-1425.
59. Ward MM, Reveille JD, Learch TJ, et al. Occupational physical activities and long-term functional and radiographic outcomes in patients with ankylosing spondylitis. Arthritis Rheum 2008; 59:822-832. An important study showing that physically demanding work has a negative influence on function and radiographic damage in patients with ankylosing spondylitis. (Pubitemid 351847565)
60. Elyan M, Khan MA. Does physical therapy still have a place in the treatment of ankylosing spondylitis? Curr Opin Rheumatol 2008; 20:282-286.
61. Dubey SG, Leeder J, Gaffney K. Physical therapy in anti-TNF treated patients with ankylosing spondylitis. Rheumatology (Oxford) 2008; 47:1100-1101. (Pubitemid 351865943)
62. Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2008:CD002822. An important review on the efficacy of physiotherapy in ankylosing spondylitis.
63. Herold M, Lind-Albrecht G. Radon within therapeutic strategies of ankylosing spondylitis. Wien Med Wochenschr 2008; 158:209-212. (Pubitemid 351702557)
64. Durmus D, Alayli G, Cil E, Canturk F. Effects of a home-based exercise program on quality of life, fatigue, and depression in patients with ankylosing spondylitis. Rheumatol Int 2008. [Epub ahead of print]
65. Nghiem FT, Donohue JP. Rehabilitation in ankylosing spondylitis. Curr Opin Rheumatol 2008; 20:203-207. (Pubitemid 351339894)
66. Ehlebracht-König I, Bönisch A. Patient education in the early treatment of ankylosing spondylitis and related forms of spondylarthritis. Wien Med Wochenschr 2008; 158:213-217; 57. (Pubitemid 351702558)
67. Lee EN, Kim YH, Chung WT, Lee MS. Tai chi for disease activity and flexibility in patients with ankylosing spondylitis: a controlled clinical trial. Evid Based Complement Alternat Med 2008; 5:457-462.
68. Badsha H, Tak PP. Can Islamic prayers benefit spondyloarthritides? Case report of a patient with ankylosing spondylitis and increased spinal mobility after an intensive regimen of Islamic prayer. Rheumatol Int 2008; 28:1057-1059.
69. Gurcay E, Yuzer S, Eksioglu E, et al. Stanger bath therapy for ankylosing spondylitis: Illusion or reality? Clin Rheumatol 2008; 27:913-917.
70. Adam O. Ankylosing spondylitis and convenient nutrition. Wien Med Wochenschr 2008; 158:294-297.
71. Bhan S, Eachempati KK, Malhotra R. Primary cementless total hip arthroplasty for bony ankylosis in patients with ankylosing spondylitis. J Arthroplasty 2008; 23:859-866.
72. Brox JI, Helle A, Sørensen R, et al. Functional outcome after lumbar closing wedge osteotomy in ankylosing spondylitis. Int Orthop 2008. [Epub ahead of print]
73. Pigge RR, Scheerder FJ, Smit TH, et al. Effectiveness of preoperative planning in the restoration of balance and view in ankylosing spondylitis. Neurosurg Focus 2008; 24:E7.
74. Mahesh BH, Jayaswal A, Bhan S. Fracture dislocation of the spine after total hip arthroplasty in a patient with ankylosing spondylitis with early pseudoarthrosis. Spine J 2008; 8:529-533. (Pubitemid 351608956)
75. Dinichert A, Cornelius JF, Lot G. Lumboperitoneal shunt for treatment of dural ectasia in ankylosing spondylitis. J Clin Neurosci 2008; 15:1179-1182.
76. Ahn NU, Ahn UM, Nallamshetty L, et al. Cauda equina syndrome in ankylosing spondylitis (the CES-AS syndrome): meta-analysis of outcomes after medical and surgical treatments. J Spinal Disord 2001; 14:427-433.
77. Conti F, Ceccarelli F, Priori R, et al. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids: clinical efficacy extended to patients on systemic antitumour necrosis factor alpha. Ann Rheum Dis 2008; 67:1787-1790.
78. Alstergren P, Larsson PT, Kopp S. Successful treatment with multiple intra-articular injections of infliximab in a patient with psoriatic arthritis. Scand J Rheumatol 2008; 37:155-157.
79. Ahern MJ, Campbell DG, Weedon H, et al. Effect of intra-articular infliximab on synovial membrane pathology in a patient with a seronegative spondyloarthropathy. Ann Rheum Dis 2008; 67:1339-1342.
80. Hollan I, Saatvedt K, Almdahl SM, et al. Spondylarthritis: a strong predictor of early coronary artery bypass grafting. Scand J Rheumatol 2008; 37:18-22. An epidemiologic study suggesting that SpAs are a stronger risk factor for CVD than the known conventional factors.
81. Tam LS, Tomlinson B, Chu TT, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls: the role of inflammation. Rheumatology (Oxford) 2008; 47:718-723. (Pubitemid 351619219)
82. Migliore A, Massafra U, Capuano A, Martin SM. Combined use of teriparatide and TNFalpha blockade: safety. Aging Clin Exp Res 2007; 19 (3 Suppl):18-20.
83. Cepeda EJ, Williams FM, Ishimori ML, et al. The use of antitumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008; 67:710-712. (Pubitemid 351571938)
84. Mikhail M, Weinberg JM, Smith BL. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus. Arch Dermatol 2008; 144:453-456. (Pubitemid 351581101)
85. Cobo-Ibáñez T, del Carmen Ordóñez M, Muñoz-Fernández S, et al. Do TNF-blockers reduce or induce uveitis? Rheumatology (Oxford) 2008; 47:731-732.
86. Coates LC, McGonagle DG, Bennett AN, et al. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis. Ann Rheum Dis 2008; 67:729-730.
87. Song IH, Appel H, Haibel H, et al. New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept. Rheumatol 2008; 35:532-536.
88. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 2008; 16:1-8. A review on the paradoxical side effect of anti-TNF agents of induction of psoriatic skin lesions in patients with rheumatic and other diseases, who did not have psoriasis before.
89. Carter JD, Gerard HC, Hudson AP. Psoriasiform lesions induced by tumour necrosis factor antagonists: a skin-deep medical conundrum. Ann Rheum Dis 2008; 67:1181-1183.
90. Borrás-Blasco J, Gracia-Perez A, Nuñez-Cornejo C, et al. Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab. J Clin Pharm Ther 2008; 33:321-325.
91. Rosen T, Martinelli P. Erythema nodosum associated with infliximab therapy. Dermatol Online J 2008; 14:3. (Pubitemid 351669211)
92. Louie GH, Chitkara P, Ward MM. Relapse of sarcoidosis upon treatment with etanercept. Ann Rheum Dis 2008; 67:896-898. (Pubitemid 351829400)
93. Toussirot E, Pertuiset E, Kantelip B, Wendling D. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol 2008; 26:471-475. (Pubitemid 352003220)
94. Kain T, MacGregor D, Buchanan RR, et al. Erythema multiforme with tumour necrosis factor inhibitors: a class effect? Ann Rheum Dis 2008; 67:899-900.
95. Garcovich S, Manco S, Zampetti A, et al. Onset of lichen planopilaris during treatment with etanercept. Br J Dermatol 2008; 158:1161-1163.
96. Marakli SS, Uzun S, Ozbek S, Tuncer I. Dermatitis herpetiformis in a patient receiving infliximab for ankylosing spondylitis. Eur J Dermatol 2008; 18:88-89. (Pubitemid 351158186)
97. Pelivani N, Hassan AS, Braathen LR, et al. Alopecia areata universalis elicited during treatment with adalimumab. Dermatology 2008; 216:320-323.
98. Fabre C, Dereure O. Worsening alopecia areata and de novo occurrence of multiple halo nevi in a patient receiving infliximab. Dermatology 2008; 216:185-186. (Pubitemid 351158591)
99. Pfueller CF, Seipelt E, Zipp F, Paul F. Multiple sclerosis following etanercept treatment for ankylosing spondylitis. Scand J Rheumatol 2008; 37:397-399.
100. Loustau V, Foltz V, Bruneteau G, et al. Diagnosis of amyotrophic lateral sclerosis in a patient treated with TNFalpha blockers for ankylosing spondylitis: fortuitus association or new side effect of TNFalpha blockers? Joint Bone Spine 2008. [Epub ahead of print]
101. Hanaoka BY, Libecco J, Rensel M, Hajj-Ali RA. Peripheral mononeuropathy with etanercept use: case report. J Rheumatol 2008; 35:182.
102. Kiltz U, Fendler C, Braun J. Neuromuscular involvement in rheumatic patients treated with antitumor necrosis factor therapy: three examples. J Rheumatol 2008; 35:2074-2076.
103. Slusher JR, Maldonado ME, Mousavi F, Lozada CJ. Central nervous system Aspergillus fumigatus presenting as cranial nerve palsy in a patient with ankylosing spondylitis on anti-TNF therapy. Rheumatology (Oxford) 2008; 47:739-740. (Pubitemid 351619229)
104. Gonnet-Gracia C, Barnetche T, Richez C, et al. Antinuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. Clin Exp Rheumatol 2008; 26:401-407.
105. Bacquet-Deschryver H, Jouen F, Quillard M, et al. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol 2008; 28:445-455.
106. Viguier M, Richette P, Aubin F, et al. Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis. Arthritis Rheum 2008; 58:1796-1802. An important report on possible side effects of efalizumab and on induction of arthritis. (Pubitemid 351847534)
107. Mielke F, Schneider-Obermeyer J, Dörner T. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. Ann Rheum Dis 2008; 67:1056-1057. (Pubitemid 351956683)
108. Cohen JD. Successful treatment of psoriatic arthritis with rituximab. Ann Rheum Dis 2008; 67:1647-1648.
109. Wick RR, Nekolla EA, Gaubitz M, Schulte TL. Increased risk of myeloid leukaemia in patients with ankylosing spondylitis following treatment with radium-224. Rheumatology (Oxford) 2008; 47:855-859. (Pubitemid 351796372)